Press "Enter" to skip to content

Hiroyuki Shimada.

Baker, M.D., Mary L. Schmidt, M.D., Susan L. Cohn, M.D., John M. Maris, M.D., Wendy B. London, Ph.D., Allen Buxton, M.S., Daniel Stram, Ph.D., Robert P. Castleberry, M.D., Hiroyuki Shimada, M.D., Anthony Sandler, M.D., Robert C. Shamberger, M.D., A. Thomas Appear, M.D., C. Patrick Reynolds, M.D., Ph.D., Robert C. Seeger, M.D., and Katherine K. Matthay, M.D. For the Children’s Oncology Group: Outcome after Reduced Chemotherapy for Intermediate-Risk Neuroblastoma Neuroblastoma is the most common extracranial good tumor in childhood, accounting for 50 percent of neoplasms diagnosed in the initial year of life.1 This disease has a heterogeneous course, ranging from spontaneous regression to inexorable progression and death, according to the biologic top features of the tumor.2-6 Identification of risk groups based on clinical and molecular prognostic variables has allowed tailoring of therapy to improve outcomes and minimize the risk of deleterious effects of therapy.7-14 In 1998, the Children’s Oncology Group established a system of risk stratification for neuroblastoma that was predicated on scientific data and tumor-derived biologic data .5,6 Stage 4S denotes a special metastatic stage of neuroblastoma in infants with a primary tumor that is restricted to one aspect of the midline and with metastatic sites limited to the liver, skin, bone marrow, or a combination of these sites .The scholarly study team said therefore that when it comes to nicotine susceptibility, some individuals are avoiders while others are choosers. Griffiths stated he hoped the findings would result in new means of treating and avoiding addiction, a topic of developing importance as the marketplace expands for electronic smokes.

Agilux implements Thermo Watson LIMS for bioanalytical services Agilux Laboratories, a company of biotech and pharmaceutical solutions, today announced that it has completed the validation and implementation of the Thermo Watson Laboratory Information Management System for the business’s bioanalytical solutions.